Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind Fixed-Dose Study of SM-13496 and Placebo in the Treatment of Schizophrenia.

Next Previous
Search
Trial Profile

A Double-Blind Fixed-Dose Study of SM-13496 and Placebo in the Treatment of Schizophrenia.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Sumitomo Pharma America; Sumitomo Pharmaceuticals America

    • Most Recent Events

    • 09 Nov 2021 Results of pooled analysis evaluating novelty of a safety profile of a drug in a new class (in clinical trials), against that of those already on the market (using pharmacovigilance data) published in the Clinical Drug Investigation
    • 20 Sep 2016 Results of pooled, post hoc analysis of this and other four trials presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 20 Sep 2016 Results of pooled, post hoc analysis of this trial and other 4 trials were presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top